2-Bromo-3-methyl-5-nitropyridine CAS:23132-21-0

2-Bromo-3-methyl-5-nitropyridine

Chemical Name:2-Bromo-3-methyl-5-nitropyridine
CAS.NO:23132-21-0
Synonyms:2-Bromo-3-methyl-5-nitropyridine
2-bromo-3-methyl-5-nitro-pyridine
6-Brom-5-methyl-3-nitropyridin
2-Bromo-5-nitro-3-picoline
Molecular Formula:C6H5BrN2O2
Molecular Weight:217.02000
 
Physical and Chemical Properties:
Density:
Melting point:57-58ºC
Boiling point:ºC
Flash point:ºC
Index of Refraction:
 
Specification:
Appearance:Yellow to brown crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



We are professional 2-Bromo-3-methyl-5-nitropyridine manufacturer and 2-Bromo-5-nitro-3-picoline supplier in China, We offer quality 6-Brom-5-methyl-3-nitropyridin you can fully trust, also we have India factory and producer of 2-bromo-3-methyl-5-nitro-pyridine,Pls send inquiry of 6-Brom-5-methyl-3-nitropyridin CAS:23132-21-0 to info@nbinno.com if you have any interests, thank you!


Related News: “We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”5-AMINO-2-BROMOBENZOIC ACID Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.3,4-Difluoro-2-methylbenzoic acid CAS:157652-31-8 Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business.Methyl 3-Fluorobenzoate CAS:455-68-5 Our pharma and biotech offering includes registration and commercialization of products through in-licensing and flexible partnerships.At the same time, due to the increase in production costs and environmental protection cost pressures in Europe and the United States, as well as the improvement of process technology, production quality, and registration and certification capabilities of China’s bulk drug manufacturers, bulk drug companies have accelerated their transfer to China, and the bulk drug industry in China has produced Scale continues to increase.